Michelle Wesso

Synexa Life Sciences

Synexa offers deep expertise in biomarker selection and panel design for each phase of clinical development. Our biomarker programs are tailor-made to clients'​ needs, usually involving considerable up-front scientific collaboration. Our culture is research-based with scientists involved in all lab activities and analysis. This approach is critical to solving challenging problems in new assay development and to the identification of new insights into the clinical pharmacology of the drug. We help clients interpret the results of the biomarker analysis, often in light of the clinical data, to advise on implications for the drug in question.